ライフサイエンスコーパス: therapy naive

1 bavirin (null responders), and 32 (39%) were therapy naive; 39 (48%) were African American.

2 bel, non-inferiority trial in antiretroviral-therapy-naive adults (age >/=18 years) with documented H

3 riority study, HIV-1-infected antiretroviral therapy-naive adults with HIV-1 RNA concentration of 100

4 estrant and Anastrozole Compared in Hormonal Therapy Naive Advanced Breast Cancer) trial.

5 Forty antiretroviral-therapy-naive, age- and CD4-matched women and men were t

6 Antiretroviral therapy-naive and AIDS-free individuals were followed fr

7 roves progression-free survival in endocrine therapy-naive and endocrine therapy-resistant metastatic

8 o lopinavir-ritonavir in both antiretroviral therapy-naive and protease inhibitor-experienced patient

9 infected individuals who are antiretroviral therapy naive as well as in those who are receiving high

10 -infected individuals who are antiretroviral therapy-naive as well as those who are receiving highly

11 with undetectable virus levels (TxHIV), and therapy-naive aviremic elite controllers (EC).

12 Following protease inhibitor therapy, naive CD4+ T cells increased only if they were

13 s in a cross-sectional cohort of 815 Italian therapy-naive CHC patients.

14 led a heterogeneous cohort of antiretroviral therapy-naive children (age, 3 months to 18 years); pati

15 cell counts remained stable over 24 weeks in therapy-naive children and decrease slightly in previous

16 CD4 counts in perinatally HIV-infected, therapy-naive children in the Paediatric European Networ

17 was to assess the activity of vinblastine in therapy-naive children.

18 ting CRF02_A/G-IbNG-infected, antiretroviral therapy-naive female commercial sex workers in Dakar, Se

19 Fifteen renal allograft recipients with therapy-naive HCV genotype (GT) 1a, 1b, or 4 were treate

20 responses in 23 highly active antiretroviral therapy naive HIV-infected patients.

21 Antiretroviral therapy-naive HIV-1 infected infants experience poor vir

22 s in peripheral blood samples from groups of therapy-naive HIV-1-infected (n = 21) and HIV-2-infected

23 t memory subpopulations in 20 antiretroviral therapy-naive HIV-1-infected individuals at approximatel

24 Therapy-naive HIV-1-infected patients without baseline r

25 ellular fractions of semen from 74 antiviral therapy-naive HIV-1-seropositive men and 53 paired blood

26 ations (DRM), including among antiretroviral therapy-naive HIV-infected individuals.

27 from 36 HIV-uninfected and 30 antiretroviral therapy-naive HIV-infected men without known CV risk fac

28 omography in 35 asymptomatic, antiretroviral-therapy-naive, HIV-1-infected adults with latent tubercu

29 n-label, multicenter study in antiretroviral therapy-naive, HIV-1-infected adults.

30 vudine and lamivudine, in 653 antiretroviral therapy-naive human immunodeficiency virus (HIV) type 1-

31 A5202 randomized antiretroviral therapy-naive human immunodeficiency virus-infected subj

32 e of the genital origin of HIV in semen from therapy naive individuals and men receiving suppressive

33 ve, M. tuberculosis infected, antiretroviral therapy naive individuals following completion of preven

34 tis C virus (HCV)-coinfected, antiretroviral therapy-naive individuals before, during, and after pegy

35 including 15 HIV-1-infected, antiretroviral therapy-naive men starting once-daily treatment with DTG

36 Dynamic (18)F-FDG PET/CT was performed on 20 therapy-naive NSCLC patients for whom primary surgical r

37 itudinal blood samples of recently infected, therapy-naive participants were interrogated with UDS.

38 Therapy-naive patients (n = 14,700) were followed from e

39 blind, comparative trial, 653 antiretroviral therapy-naive patients received lopinavir/ritonavir or n

40 hock protein (HSP) receptor, was observed in therapy-naive patients who had no evidence of ongoing vi

41 e antiretroviral therapy (HAART), but not in therapy-naive patients who had substantial levels of pla

42 on, we evaluated HIV-positive antiretroviral therapy-naive patients who were on lithium therapy.

43 ples from castration-resistant compared with therapy-naive patients.

44 ential therapeutic option for antiretroviral-therapy-naive patients.

45 AC after radiotherapy failure than those in therapy-naive PCa, prostatic intraepithelial neoplasia,

46 ars old with unresectable and/or progressive therapy-naive PLGG were eligible.

47 following characteristics, especially among therapy-naive potential source partners: seminal cytomeg

48 750 tumors of diverse origin, including >150 therapy-naive, primary, and recurrent SCCHNs.

49 sion of ANXA1 and cytokines were assessed in therapy-naive rhesus macaques during early and chronic s

50 esults indicate HIV-positive, antiretroviral therapy-naive South-African blacks with two APOL1 risk a

51 recurrent SCCHN compared to patient-matched therapy naive specimens.

52 s of CXCL13 in HIV-1-infected antiretroviral therapy-naive subjects correlated with viral load and we

53 Eligible patients were endocrine therapy-naive, with WHO performance status 0-2, and at l

54 rogression and survival in an antiretroviral therapy-naive Zimbabwean cohort (n = 312).